REAL WORLD EVIDENCE NEEDS IN ONCOLOGY:
White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid.
As the second most common cancer in men worldwide, prostate cancer poses substantial healthcare burdens and necessitates continuous research and innovation in treatment strategies.
OXON has analyzed the results of the trials presented at ESMO 2023, and examined their potential impact on current clinical guidelines and practices in prostate cancer treatment. By summarizing these studies in this white paper, we aim to provide a more comprehensive overview to help guide the RWE gaps in this cancer.
To download the white paper please complete the following form: